cms.bioaccessla.com

Blog

  • Gailumed Alojamiento de Licencias LATAM vs bioaccess® LATAM Launch Subscription

    Gailumed shows up when manufacturers search for a Latin American registration holder or sanitary-registration partner. This article uses only what Gailumed publishes on its own site (gailumed.com/servicios-para-america-latina), then compares it with the multi-country subscription from bioaccess®. It is a practitioner comparison, not a teardown.

    What Gailumed publishes

    Gailumed publishes a Latin America services page that offers to register products, host ("alojar") the licenses, and act as legal representative across the region. Medical devices are listed among other health product classes.

    Gailumed vs bioaccess®

    Dimension Gailumed bioaccess®
    Public product Registration + license hosting + legal representation LATAM Launch Subscription: registration, in-country holder, certified translations, government fees, tecnovigilancia (import shipments quoted separately)
    Geography Multi-country Latin America (countries per its services page) 19 LATAM markets
    Public pricing None published USD 7,500 per year per country for the first device family
    Holder vs distributor See the provider’s own terms Holds through its own in-country entities, with defined transfer provisions; the registration is never leverage
    Bridge from a clinical trial None published Trial-to-Market Bridge: 20% off for bioaccess® clinical-trial clients

    Where each one fits

    If your portfolio mixes devices with other health products and you want one hosting vendor for all of them, Gailumed advertises that job.

    The LATAM Launch Subscription from bioaccess® is a different product. bioaccess® registers already FDA-cleared or CE-marked devices and holds them through its own in-country entities across 19 Latin American markets, including COFEPRIS, ANVISA, INVIMA, ANMAT, ISP and DIGEMID. The published card is USD 7,500 per year per country for the first device family, with government submission fees, certified or sworn translations, the in-country titular or holder, and tecnovigilancia inside the fee (importer-of-record shipments are priced separately on the hub). Multi-country discounts are 10% at three or more countries and 15% at five or more. The registration is held for the manufacturer’s benefit, with defined transfer provisions if you ever change partners or set up your own entity.

    One country and one local partner is enough? Hire the firm that publishes that job. Several LATAM labels under one holder who is not your distributor? Start at bioaccess® market access, read the LATAM importer of record guide, try the LATAM Launch Calculator, or request a registration quote.

    Competitor facts from the Gailumed public pages linked above, reviewed for bioaccess® competitive research (Aug–Oct 2026). Claims are theirs. No invented clients, prices or contacts.

  • SPI Americas Hosting Regulatorio vs bioaccess® LATAM Registration Holder

    SPI Americas shows up when manufacturers search for a Latin American registration holder or sanitary-registration partner. This article uses only what SPI Americas publishes on its own site (spiamericas.com/asuntos-regulatorios), then compares it with the multi-country subscription from bioaccess®. It is a practitioner comparison, not a teardown.

    What SPI Americas publishes

    SPI Americas is a Colombia-based firm with regulatory, IP and corporate practices. Its regulatory affairs page sells "hosting" ("parqueadero regulatorio"), where SPI becomes the party responsible before the authority, plus INVIMA dossiers, CCAA, semantic standard and tecnovigilancia. It works across several Latin American countries from Colombia, and the INVIMA work is the deepest.

    SPI Americas vs bioaccess®

    Dimension SPI Americas bioaccess®
    Public product Regulatory hosting ("parqueadero regulatorio") + INVIMA dossiers, CCAA, tecnovigilancia LATAM Launch Subscription: registration, in-country holder, certified translations, government fees, tecnovigilancia (import shipments quoted separately)
    Geography Colombia-led, multi-country Latin America 19 LATAM markets
    Public pricing None published USD 7,500 per year per country for the first device family
    Holder vs distributor See the provider’s own terms Holds through its own in-country entities, with defined transfer provisions; the registration is never leverage
    Bridge from a clinical trial None published Trial-to-Market Bridge: 20% off for bioaccess® clinical-trial clients

    Where each one fits

    If Colombia is the anchor market and you also want IP or corporate counsel from the same firm, SPI Americas is a sensible pick.

    The LATAM Launch Subscription from bioaccess® is a different product. bioaccess® registers already FDA-cleared or CE-marked devices and holds them through its own in-country entities across 19 Latin American markets, including COFEPRIS, ANVISA, INVIMA, ANMAT, ISP and DIGEMID. The published card is USD 7,500 per year per country for the first device family, with government submission fees, certified or sworn translations, the in-country titular or holder, and tecnovigilancia inside the fee (importer-of-record shipments are priced separately on the hub). Multi-country discounts are 10% at three or more countries and 15% at five or more. The registration is held for the manufacturer’s benefit, with defined transfer provisions if you ever change partners or set up your own entity.

    One country and one local partner is enough? Hire the firm that publishes that job. Several LATAM labels under one holder who is not your distributor? Start at bioaccess® market access, read the LATAM importer of record guide, try the LATAM Launch Calculator, or request a registration quote.

    Competitor facts from the SPI Americas public pages linked above, reviewed for bioaccess® competitive research (Aug–Oct 2026). Claims are theirs. No invented clients, prices or contacts.

  • Pro Pharma Research COFEPRIS Titular del Registro vs bioaccess® LATAM Launch Subscription

    Pro Pharma Research Organization shows up when manufacturers search for a Latin American registration holder or sanitary-registration partner. This article uses only what Pro Pharma Research Organization publishes on its own site (propharmaresearch.com/index.php/servicio/servicios-representante-empresa-titular-registro-sanitario-mexico), then compares it with the multi-country subscription from bioaccess®. It is a practitioner comparison, not a teardown.

    What Pro Pharma Research Organization publishes

    Pro Pharma Research Organization is a Mexican company that publishes a service page for acting as company representative and titular del registro sanitario (TRS) before COFEPRIS. The page covers pharmaceuticals, medical devices and other health products, and COFEPRIS liaison. It is broader than devices.

    Pro Pharma Research Organization vs bioaccess®

    Dimension Pro Pharma Research Organization bioaccess®
    Public product Mexico titular del registro / company representative before COFEPRIS LATAM Launch Subscription: registration, in-country holder, certified translations, government fees, tecnovigilancia (import shipments quoted separately)
    Geography Mexico 19 LATAM markets
    Public pricing None published USD 7,500 per year per country for the first device family
    Holder vs distributor See the provider’s own terms Holds through its own in-country entities, with defined transfer provisions; the registration is never leverage
    Bridge from a clinical trial None published Trial-to-Market Bridge: 20% off for bioaccess® clinical-trial clients

    Where each one fits

    If Mexico is the only market and you want a local titular that also handles pharma SKUs, Pro Pharma publishes that service.

    The LATAM Launch Subscription from bioaccess® is a different product. bioaccess® registers already FDA-cleared or CE-marked devices and holds them through its own in-country entities across 19 Latin American markets, including COFEPRIS, ANVISA, INVIMA, ANMAT, ISP and DIGEMID. The published card is USD 7,500 per year per country for the first device family, with government submission fees, certified or sworn translations, the in-country titular or holder, and tecnovigilancia inside the fee (importer-of-record shipments are priced separately on the hub). Multi-country discounts are 10% at three or more countries and 15% at five or more. The registration is held for the manufacturer’s benefit, with defined transfer provisions if you ever change partners or set up your own entity.

    One country and one local partner is enough? Hire the firm that publishes that job. Several LATAM labels under one holder who is not your distributor? Start at bioaccess® market access, read the LATAM importer of record guide, try the LATAM Launch Calculator, or request a registration quote.

    Competitor facts from the Pro Pharma Research Organization public pages linked above, reviewed for bioaccess® competitive research (Aug–Oct 2026). Claims are theirs. No invented clients, prices or contacts.

  • PharmaLex MedTech Local Affiliate Services vs bioaccess® LATAM Registration Holder

    PharmaLex (Cencora) shows up when manufacturers search for a Latin American registration holder or sanitary-registration partner. This article uses only what PharmaLex (Cencora) publishes on its own site (www.pharmalex.com/pharmalex-industry-sectors/medtech · www.pharmalex.com/pharmalex-solutions/local-affiliate-services · www.pharmalex.com/country/brazil), then compares it with the multi-country subscription from bioaccess®. It is a practitioner comparison, not a teardown.

    What PharmaLex (Cencora) publishes

    PharmaLex, part of Cencora, is a global regulatory consultancy. Its MedTech page says it arranges authorized representative and license holder services in "multiple markets," and its local-affiliate page names emerging Latin American markets "such as Brazil and Mexico." PharmaLex has a Brazil country page. The public pages do not list INVIMA, ANMAT, ISP or DIGEMID holder services one by one, and much of the MedTech content is EU MDR/IVDR work.

    PharmaLex (Cencora) vs bioaccess®

    Dimension PharmaLex (Cencora) bioaccess®
    Public product Global MedTech regulatory consulting, authorized representative / license holder arranged in multiple markets LATAM Launch Subscription: registration, in-country holder, certified translations, government fees, tecnovigilancia (import shipments quoted separately)
    Geography Brazil and Mexico named; others not enumerated 19 LATAM markets
    Public pricing Enterprise / statement of work USD 7,500 per year per country for the first device family
    Holder vs distributor See the provider’s own terms Holds through its own in-country entities, with defined transfer provisions; the registration is never leverage
    Bridge from a clinical trial None published Trial-to-Market Bridge: 20% off for bioaccess® clinical-trial clients

    Where each one fits

    If you are a large manufacturer already buying EU MDR and pharmacovigilance work from PharmaLex, adding Brazil or Mexico through the same account is fine.

    The LATAM Launch Subscription from bioaccess® is a different product. bioaccess® registers already FDA-cleared or CE-marked devices and holds them through its own in-country entities across 19 Latin American markets, including COFEPRIS, ANVISA, INVIMA, ANMAT, ISP and DIGEMID. The published card is USD 7,500 per year per country for the first device family, with government submission fees, certified or sworn translations, the in-country titular or holder, and tecnovigilancia inside the fee (importer-of-record shipments are priced separately on the hub). Multi-country discounts are 10% at three or more countries and 15% at five or more. The registration is held for the manufacturer’s benefit, with defined transfer provisions if you ever change partners or set up your own entity.

    One country and one local partner is enough? Hire the firm that publishes that job. Several LATAM labels under one holder who is not your distributor? Start at bioaccess® market access, read the LATAM importer of record guide, try the LATAM Launch Calculator, or request a registration quote.

    Competitor facts from the PharmaLex (Cencora) public pages linked above, reviewed for bioaccess® competitive research (Aug–Oct 2026). Claims are theirs. No invented clients, prices or contacts.

  • Registrar Corp / CMC Global Representation vs a LATAM Registration Holder (bioaccess®)

    Registrar Corp (CMC Medical Devices) shows up when manufacturers search for a Latin American registration holder or sanitary-registration partner. This article uses only what Registrar Corp (CMC Medical Devices) publishes on its own site (www.registrarcorp.com/medical-devices/global-representation · www.registrarcorp.com/contact/mexico-office), then compares it with the multi-country subscription from bioaccess®. It is a practitioner comparison, not a teardown.

    What Registrar Corp (CMC Medical Devices) publishes

    Registrar Corp is a long-standing U.S. FDA-compliance firm that works with CMC Medical Devices on global representation. Its representation page lists Europe, the UK, Switzerland, Australia, China, the US, India, Korea, Southeast Asia and "South America." We found no country pages naming ANVISA, COFEPRIS, INVIMA or ANMAT holder services. Registrar Corp does publish a Mexico office contact page.

    Registrar Corp (CMC Medical Devices) vs bioaccess®

    Dimension Registrar Corp (CMC Medical Devices) bioaccess®
    Public product Global authorized-representative network; Latin America described as "South America" LATAM Launch Subscription: registration, in-country holder, certified translations, government fees, tecnovigilancia (import shipments quoted separately)
    Geography "South America" (no Latin American regulator named on the page) 19 LATAM markets
    Public pricing None published for Latin America USD 7,500 per year per country for the first device family
    Holder vs distributor See the provider’s own terms Holds through its own in-country entities, with defined transfer provisions; the registration is never leverage
    Bridge from a clinical trial None published Trial-to-Market Bridge: 20% off for bioaccess® clinical-trial clients

    Where each one fits

    If you need one vendor for US Agent, EU, UK, Swiss and Asian representation and Latin America is a later thought, Registrar Corp is a reasonable global bundle.

    The LATAM Launch Subscription from bioaccess® is a different product. bioaccess® registers already FDA-cleared or CE-marked devices and holds them through its own in-country entities across 19 Latin American markets, including COFEPRIS, ANVISA, INVIMA, ANMAT, ISP and DIGEMID. The published card is USD 7,500 per year per country for the first device family, with government submission fees, certified or sworn translations, the in-country titular or holder, and tecnovigilancia inside the fee (importer-of-record shipments are priced separately on the hub). Multi-country discounts are 10% at three or more countries and 15% at five or more. The registration is held for the manufacturer’s benefit, with defined transfer provisions if you ever change partners or set up your own entity.

    One country and one local partner is enough? Hire the firm that publishes that job. Several LATAM labels under one holder who is not your distributor? Start at bioaccess® market access, read the LATAM importer of record guide, try the LATAM Launch Calculator, or request a registration quote.

    Competitor facts from the Registrar Corp (CMC Medical Devices) public pages linked above, reviewed for bioaccess® competitive research (Aug–Oct 2026). Claims are theirs. No invented clients, prices or contacts.

  • Global Regulatory Partners Brazil and Mexico Registration Holder vs bioaccess®

    Global Regulatory Partners (GRP) shows up when manufacturers search for a Latin American registration holder or sanitary-registration partner. This article uses only what Global Regulatory Partners (GRP) publishes on its own site (globalregulatorypartners.com/registration-holder-for-medical-devices-imported-from-mexico · globalregulatorypartners.com/countries/brazils-anvisa), then compares it with the multi-country subscription from bioaccess®. It is a practitioner comparison, not a teardown.

    What Global Regulatory Partners (GRP) publishes

    Global Regulatory Partners (GRP) is a Massachusetts regulatory firm with affiliates in China, Japan, Brazil and Mexico. Its public pages say GRP-Brazil is licensed by ANVISA to act as Brazilian Registration Holder, and that GRP Mexico is COFEPRIS-licensed to act as Mexico Registration Holder and local representative. The Mexico page pitches an independent holder, so a manufacturer can add distributors without handing them the dossier, and also lists importation, warehousing and distribution.

    Global Regulatory Partners (GRP) vs bioaccess®

    Dimension Global Regulatory Partners (GRP) bioaccess®
    Public product ANVISA BRH and COFEPRIS MRH through its own licensed affiliates; Mexico import, warehousing, distribution LATAM Launch Subscription: registration, in-country holder, certified translations, government fees, tecnovigilancia (import shipments quoted separately)
    Geography Brazil and Mexico 19 LATAM markets
    Public pricing None published USD 7,500 per year per country for the first device family
    Holder vs distributor See the provider’s own terms Holds through its own in-country entities, with defined transfer provisions; the registration is never leverage
    Bridge from a clinical trial None published Trial-to-Market Bridge: 20% off for bioaccess® clinical-trial clients

    Where each one fits

    If Brazil and Mexico are the only Latin American markets on the plan, and you also want GRP for China or Japan, its own-affiliate model covers that job.

    The LATAM Launch Subscription from bioaccess® is a different product. bioaccess® registers already FDA-cleared or CE-marked devices and holds them through its own in-country entities across 19 Latin American markets, including COFEPRIS, ANVISA, INVIMA, ANMAT, ISP and DIGEMID. The published card is USD 7,500 per year per country for the first device family, with government submission fees, certified or sworn translations, the in-country titular or holder, and tecnovigilancia inside the fee (importer-of-record shipments are priced separately on the hub). Multi-country discounts are 10% at three or more countries and 15% at five or more. The registration is held for the manufacturer’s benefit, with defined transfer provisions if you ever change partners or set up your own entity.

    One country and one local partner is enough? Hire the firm that publishes that job. Several LATAM labels under one holder who is not your distributor? Start at bioaccess® market access, read the LATAM importer of record guide, try the LATAM Launch Calculator, or request a registration quote.

    Competitor facts from the Global Regulatory Partners (GRP) public pages linked above, reviewed for bioaccess® competitive research (Aug–Oct 2026). Claims are theirs. No invented clients, prices or contacts.

  • THEMA Local Representative and License Holder vs bioaccess® LATAM Launch Subscription

    THEMA shows up when manufacturers search for a Latin American registration holder or sanitary-registration partner. This article uses only what THEMA publishes on its own site (www.thema-med.com/en/services/local-representative-and-license-holder · www.thema-med.com/en/medical-device-registration-argentina), then compares it with the multi-country subscription from bioaccess®. It is a practitioner comparison, not a teardown.

    What THEMA publishes

    THEMA is an Italy-based medical-device consultancy. Its local representative and license holder service page names three Latin American roles it offers: Brazilian Registration Holder (BRH), Mexican Registration Holder (MRH), and Argentina Authorized Representative (AAR). It also publishes a Peru registration explainer that describes the DIGEMID local holder. THEMA offers local representation and license holding "where required" as part of a wider EU authorized-representative network. Its Argentina page warns that changing the AAR means restarting the registration, which is the honest description of how ANMAT works.

    THEMA vs bioaccess®

    Dimension THEMA bioaccess®
    Public product Local representative / license holder in Brazil, Mexico and Argentina, inside an EU AR network LATAM Launch Subscription: registration, in-country holder, certified translations, government fees, tecnovigilancia (import shipments quoted separately)
    Geography Brazil, Mexico, Argentina named on the service page; Peru explainer 19 LATAM markets
    Public pricing None published USD 7,500 per year per country for the first device family
    Holder vs distributor See the provider’s own terms Holds through its own in-country entities, with defined transfer provisions; the registration is never leverage
    Bridge from a clinical trial None published Trial-to-Market Bridge: 20% off for bioaccess® clinical-trial clients

    Where each one fits

    If you already use THEMA as your EU authorized representative and need one or two of Brazil, Mexico or Argentina, keeping the same vendor is a fair choice.

    The LATAM Launch Subscription from bioaccess® is a different product. bioaccess® registers already FDA-cleared or CE-marked devices and holds them through its own in-country entities across 19 Latin American markets, including COFEPRIS, ANVISA, INVIMA, ANMAT, ISP and DIGEMID. The published card is USD 7,500 per year per country for the first device family, with government submission fees, certified or sworn translations, the in-country titular or holder, and tecnovigilancia inside the fee (importer-of-record shipments are priced separately on the hub). Multi-country discounts are 10% at three or more countries and 15% at five or more. The registration is held for the manufacturer’s benefit, with defined transfer provisions if you ever change partners or set up your own entity.

    One country and one local partner is enough? Hire the firm that publishes that job. Several LATAM labels under one holder who is not your distributor? Start at bioaccess® market access, read the LATAM importer of record guide, try the LATAM Launch Calculator, or request a registration quote.

    Competitor facts from the THEMA public pages linked above, reviewed for bioaccess® competitive research (Aug–Oct 2026). Claims are theirs. No invented clients, prices or contacts.

  • IzzoMed Peru Registration Holder vs bioaccess® LATAM Launch Subscription

    IzzoMed is a Lima-based company that now publishes an independent Peru registration holder offer for international medical device, IVD, and pharmaceutical manufacturers. The English page is at izzomed.com/peru-registration-holder/ and the Spanish version is at izzomed.com/es/titular-del-registro-en-peru/. The English holder page went live in late September 2026. This article uses only what IzzoMed publishes, then compares it with the multi-country subscription from bioaccess®.

    What IzzoMed publishes

    IzzoMed positions itself as a local regulatory representative and registration holder before DIGEMID, Peru’s medicines and devices authority. The holder page lists four parts: local regulatory representation, registration management, registration maintenance (renewals and modifications), and a holder structure that “can remain independent from commercial distribution.” The home page adds importation, storage through authorized healthcare infrastructure, distribution, and commercial development in Peru. IzzoMed also represents specialized oncology equipment in Peru on its own product pages. We found no public price on the site.

    The pitch is the right one for Peru. As summarized in the bioaccess® LATAM registration guide, Decreto Supremo N° 001-2024-SA permits an independent Peru registration holder, and imports still flow through a licensed droguería. A titular that is not the exclusive seller lets the manufacturer change or add distributors without losing the registro.

    IzzoMed vs bioaccess®

    Dimension IzzoMed (Peru) bioaccess®
    Public product Independent Peru registration holder / MAH, plus import, storage, distribution, and commercial support LATAM Launch Subscription: registration, in-country holder, certified translations, government fees, tecnovigilancia (import shipments quoted separately)
    Geography Peru 19 LATAM markets, including Peru (DIGEMID)
    Holder vs distributor Says representation can stay separate from a single distributor; also offers distribution and represents its own product lines Holds through its own in-country entities, with defined transfer provisions; the registration is never leverage
    Public pricing None published USD 7,500 per year per country for the first device family
    Bridge from a clinical trial None published Trial-to-Market Bridge: 20% off for bioaccess® clinical-trial clients

    Where each one fits

    If Peru is the only market and the plan is to build a local commercial channel with one partner, IzzoMed’s published offer covers that job, and it says the right things about keeping the titular separate from the seller.

    The LATAM Launch Subscription from bioaccess® is a different product. bioaccess® registers already FDA-cleared or CE-marked devices and holds them through its own in-country entities across Latin America. The bioaccess® Peru Holder covers DIGEMID registration through the licensed droguería pathway, and the same holder doctrine applies next to COFEPRIS, ANVISA, INVIMA, and ANMAT. The published card is USD 7,500 per year per country for the first device family, with government submission fees, certified or sworn translations, the in-country titular or holder, and tecnovigilancia inside the fee. Import shipments are quoted separately. Multi-country discounts are 10% at three or more countries and 15% at five or more. The registration is held for the manufacturer’s benefit, with defined transfer provisions if you ever change partners or set up your own entity.

    One country and a local titular is enough? Hire the shop that publishes that job. Several LATAM labels under one holder who is not your distributor? Start at bioaccess® market access, try the LATAM Launch Calculator, or request a registration quote.

  • Dr. Carlos Rojas, Bradford Hill: A Chile FIH Principal Investigator Is Not the CRO

    If you searched Dr. Carlos Rojas Bradford Hill, Carlos Rojas first-in-human Chile, or Sona THT principal investigator, you found a real investigator in the public record. Dr. Carlos Rojas is named by Sona Nanotech as the principal investigator of its first-in-human Targeted Hyperthermia Therapy study and as executive director of Bradford Hill in Santiago, Chile. A principal investigator is not the CRO.

    bioaccess®’s position is simple and it is not adversarial: the investigator and the site run the cases. The First-in-Human CRO still owns ISP authorization, Law 20.120 Ethical-Scientific Committee review, investigational import, insurance, ISO 14155 monitoring, and the FDA 21 CFR 812.28 package. Emailing the PI is a good way to test investigator interest. It is not a regulatory plan.

    What the public record says

    • Sona Nanotech, 16 June 2025: clinical trial agreement with Bradford Hill Investigación Clínica, Santiago, for an early feasibility study of THT in up to ten advanced melanoma patients; Dr. Carlos Rojas named principal investigator and Bradford Hill executive director.
    • Sona Nanotech, 20 October 2025: study completion; Dr. Rojas, quoted as executive director of the Bradford Hill Clinical Cancer Research Center, described rapid responses in patients who had exhausted standard immunotherapy.
    • ClinicalTrials.gov NCT06894407: industry sponsor Sona Nanotech Inc, DEVICE_FEASIBILITY, enrollment 10, single location Bradford Hill, Santiago, Chile; no CRO or collaborator listed; record updated 2 October 2026 to COMPLETED.

    The facility-level page is here: Bradford Hill, Santiago: the site is not the CRO.

    PI versus CRO

    Workstream Principal investigator First-in-Human CRO
    Clinical judgment and cases Yes Supports with protocol training and monitoring
    ISP file and amendments Signs what the site must sign Prepares, submits, and answers deficiencies
    Device import No Importer of record for the investigational device
    ISO 14155 monitoring and TMF Keeps source documents Monitors, reconciles, and closes out
    FDA 21 CFR 812.28 Provides site data Builds the foreign-data narrative for the U.S. submission

    FAQ

    Did bioaccess® work on Dr. Rojas’s Sona study?
    No. This page reports public sources only and claims no role in that study.

    Does bioaccess® only work in Chile?
    No. bioaccess® is the First-in-Human CRO for medical devices in Latin America since 2010, and it still runs clinical trials in Colombia as well as Chile, Panama, and the rest of the platform.

    Sources: Sona Nanotech press releases of 16 June 2025 and 20 October 2025; ClinicalTrials.gov NCT06894407. Public sources only.

  • Contract Research Organization Companies: How to Compare Them

    Contract Research Organization Companies: How to Compare Them

    The leading contract research organization companies include IQVIA, ICON plc, Thermo Fisher Scientific (PPD), Parexel, Syneos Health, Fortrea, TFS HealthScience, PharmaLegacy Research, and WuXi AppTec. The sections below profile each firm and cover four selection variables, with guidance on when a regional specialist outperforms a global firm.

    The CRO market is substantial. Member companies of the Association of Clinical Research Organizations generated $89.4 billion in revenue in 2025, reflecting how central outsourced clinical operations have become to drug and device development. Sponsors now face a real choice: a global full-service firm with operations across dozens of countries, or a specialty or regional partner with deeper expertise in a specific phase, therapeutic area, or geography. The right answer depends on your program, not on which name appears most often in industry rankings.

    Top Contract Research Organization Companies at a Glance

    The nine CROs below represent the most commonly evaluated options across global, mid-size, and specialty segments. Pricing is not publicly listed for any of them; cost structures vary by scope, phase, and geography.

    CRO Primary Focus Geographic Reach
    IQVIA Clinical research, lab services, analytics 100+ countries
    ICON plc Biotech-focused clinical research, digital measurement 93 countries
    Thermo Fisher Scientific (PPD) End-to-end clinical development, 20 therapeutic areas Global lab and logistics network
    Parexel International Global clinical trials, AI-assisted trial prediction Global
    Syneos Health Integrated clinical-to-commercial 110+ countries
    Fortrea Phase I, IV clinical research execution Global
    TFS HealthScience Customized trials, strategic resourcing 50 countries
    PharmaLegacy Research Non-clinical lab services, drug discovery U.S.-based facilities
    WuXi AppTec Integrated research, development, manufacturing Global

    Global Full-Service CROs: IQVIA, ICON, PPD, Parexel, and Syneos Health

    The largest global CROs offer therapeutic breadth, deep site networks, and integrated technology platforms. They suit large Phase II and IV programs that require simultaneous enrollment across multiple continents.

    IQVIA operates in more than 100 countries and carries a large committed backlog, reflecting the scale of its pipeline. The company rebranded its lab services division as IQVIA Laboratories in 2024. Its analytics and technology layer suits sponsors who need real-world data alongside trial execution.

    ICON plc was identified as the most used CRO for new study starts in 2024, with operations across 93 countries and a particular emphasis on biotech sponsors and digital measurement tools. In 2026, ICON disclosed an audit investigation indicating minor revenue overstatements in prior years, which sponsors should factor into due diligence.

    Thermo Fisher Scientific (PPD) covers 20 therapeutic areas and draws on Thermo Fisher's global lab and logistics infrastructure following its acquisition of PPD in 2021. Sponsors running studies that require complex sample analysis alongside clinical execution benefit from that integration.

    Parexel International applies AI to predict trial success probabilities and is backed by EQT and Goldman Sachs following a private buyout. That private structure gives it operational flexibility, though it also means less public financial disclosure than listed peers.

    Syneos Health runs an integrated clinical-to-commercial model across more than 110 countries. Taken private in 2023, it no longer publishes audited financial results, so sponsors evaluating financial stability will need to request that information directly.

    Specialty and Mid-Size CROs: Fortrea, TFS HealthScience, PharmaLegacy, and WuXi AppTec

    Specialty and mid-size CROs are worth considering when a sponsor needs focused expertise, a more accessible cost structure, or a tighter operational relationship than a global firm typically offers.

    Fortrea was spun off from Labcorp as a standalone CRO and has since sold non-core units to concentrate exclusively on Phase I through IV clinical research execution. That narrowed focus means sponsors work with a team whose entire operation is built around trial delivery, not lab services or manufacturing.

    TFS HealthScience supports more than 150 indications across oncology, neuroscience, and other key areas in 50 countries. Its governance model gives sponsors direct access to executive leadership, which matters on programs where fast decisions reduce timeline risk.

    WuXi AppTec covers research, development, and manufacturing on a single integrated platform. Sponsors who need to move from early-phase clinical work into manufacturing without switching vendors find that breadth useful.

    PharmaLegacy Research focuses on non-clinical laboratory services, drug discovery, and in vitro assays, with support for more than 600 IND applications and 380,000 square feet of facility space. FDA inspections in 2025 cited deficiencies in quality assurance and equipment maintenance, per biolegacyresearch.com, so sponsors should review current inspection records before engaging.

    How Do You Choose the Right CRO for Your Program?

    Selecting a CRO comes down to matching four variables: financial capacity, therapeutic expertise, technology, and geographic access. Working through them in order keeps brand recognition from distorting the decision.

    A structured approach helps. Comparing CROs across these dimensions before issuing an RFP surfaces mismatches early and saves time downstream.

    Step 1: Evaluate financial stability. A CRO that cannot sustain your program through a 24-month trial is a liability. Review revenue trends, backlog figures, and ownership structure. Private firms with no public reporting require direct disclosure requests [S1].

    Step 2: Verify therapeutic and phase expertise. A large CRO with a broad oncology network may have few sites qualified for first-in-human or medical device work, which extends activation timelines on early-phase programs. Ask for case examples specific to your indication and phase, including site counts and prior activation times [S2].

    Step 3: Assess technology integration. AI-assisted site selection, electronic data capture, and decentralized trial tools affect both timeline and data quality. Ask how the CRO's platform integrates with your existing systems [S3]. According to Technavio's 2026 report, the right CRO partnership can cut trial startup times by more than 25%. That advantage is largest when the CRO already holds active ethics committee approvals and pre-qualified sites in your target country.

    Step 4: Review geographic reach. Site network depth in your target countries drives enrollment speed. Ask each CRO candidate for site counts in your target country, the number of those sites with active ethics committee approvals, and median activation timelines for your indication. Phase III trials average 0.84 patients per site per month, according to Nature Reviews Drug Discovery, a benchmark that highlights how site selection directly affects enrollment pace. A CRO with pre-qualified sites and existing ethics committee relationships in your target region compresses that timeline compared to one entering the market for the first time [S4].

    When Is a LATAM-Focused Regional CRO the Better Choice?

    A regional LATAM CRO outperforms a global firm in three specific scenarios: first-in-human and early feasibility studies where speed and per-patient cost matter most, programs targeting FDA IDE or IND submissions that need OUS data collected under ISO 14155, and device market entry across multiple Latin American countries where in-country regulatory expertise is non-negotiable.

    Global CROs carry overhead structures that make them expensive for early-phase programs. A regional specialist with pre-qualified sites, standing Ethics Committee relationships, and in-country regulatory staff can activate studies faster and at lower per-patient cost.

    bioaccess® is a Miami-headquartered contract research organization serving MedTech, biopharma, and radiopharma sponsors through two service lines. The FIH-12™ program is a nine-workstream, 12-month engagement covering FDA Pre-Sub and IDE/IND pathway alignment, protocol development, site activation, patient enrollment, data management, and delivery of a submission-ready clinical evidence package. The LATAM Launch Subscription handles in-country holder and Importer of Record registration for FDA-cleared (510(k) or PMA) or CE-marked devices across ANVISA, INVIMA, COFEPRIS, ANMAT, ISP, DIGEMID, and other regulators across 19 markets.

    Prices and plan limits verified as of October 2026.

    FAQs

    Who is the largest contract research organization in the world?

    IQVIA is widely cited as the largest CRO by revenue, with operations in more than 100 countries and a large committed backlog. ICON plc ranks among the top tier as well, identified as the most used CRO for new study starts in 2024. Scale matters for large Phase III and IV programs, but it is not the primary selection criterion for early-phase or regionally focused work.

    What is the difference between a full-service CRO and a functional service provider?

    A full-service CRO manages the entire trial from protocol design through data submission. A functional service provider (FSP) delivers a defined subset of services, such as data management or site monitoring, under the sponsor's operational oversight. FSP models suit sponsors with internal clinical teams who need specific capacity; full-service models suit sponsors who want a single accountable partner for the whole program.

    How long does it typically take to activate a clinical trial site?

    At cancer centers, median activation timelines decreased to 250 days in 2024, per aaci-cancer.org, though that figure reflects oncology-specific conditions. Timelines vary by country, therapeutic area, and whether the CRO holds pre-existing ethics committee and regulatory relationships.

    What does GCP compliance mean when evaluating a CRO?

    Good Clinical Practice (GCP) compliance means the CRO conducts trials according to ICH E6 guidelines, which govern trial design, conduct, monitoring, recording, and reporting to protect participant safety and data integrity. For medical device trials, ISO 14155 is the applicable standard. Data collected under these standards is accepted for U.S. FDA IDE and IND submissions. Ask any CRO candidate for recent audit records and inspection history.

    How do per-patient costs vary between regions?

    Per-patient costs are substantially lower in Latin America than in the United States or Western Europe. That difference can extend a sponsor's financial runway on early-phase programs where enrollment is limited and every dollar of capital affects the path to a next funding milestone.

    Conclusion

    Selecting among contract research organization companies is a matching exercise, not a ranking exercise. Global full-service firms offer therapeutic breadth and multinational site networks suited to large, late-phase programs. Specialty and regional CROs offer focused expertise, faster activation, and more accessible cost structures for early-phase and geographically specific work.

    Start by defining your program's phase, therapeutic area, target countries, and submission pathway. Evaluate each CRO candidate against those four variables before reviewing price. A CRO with the right regulatory relationships and pre-qualified sites in your target region will almost always outperform a larger firm entering that market for the first time.